Chris Picardo

Board Member at Aizen Therapeutics
Seattle, Washington, United States

Chris Picardo is a Partner at Madrona Venture Group and serves as a board member or observer for several companies including Aizen Therapeutics, Archon Biosciences, Knock, and Ovation.io. He previously worked as an investor at Madrona Venture Group, a business analyst at McKinsey & Company, and held finance and analyst roles at Rockets of Awesome and MD Sass.

Insurtech Faye raises $50M led by Madrona, bringing total funding to $100M as it scales AI and international growth

Faye, a Richmond-based travel insurance app, raised $50 million led by Madrona, bringing its total funding to $100 million since 2022 to scale AI, expand internationally, and improve claims and UX; the company reported millions of customers and $100 million in annualized revenue last year. Co-founder and CEO Elad Schaffer called the raise a shift from startup to scale-up as Faye pursues growth toward a possible future IPO.

Curt Medeiros on Revolutionizing Precision Medicine and Scaling Ovation

Imagine a future where healthcare isn't just reactive but deeply personalized — where every patient gets the right treatment at the right time based on a precise understanding of their biology. This is the future Ovation is building, and on this week's Founded & Funded, Madrona Partner Chris Picardo dives into it all with Ovation CEO Curt Medeiros. From transforming underutilized clinical data into rich multiomics datasets to forging industry-leading partnerships with companies like Illumina, Curt shares how Ovation is shaping the future of precision medicine. He also opens up about the challenges of building a scalable, privacy-first platform, the…

Chris Picardo: Madrona Partner on Tech-Driven Life Science Innovation

Chris Picardo is a Partner at Madrona. Chris joined Madrona in 2017. As a partner on the investment team, Chris focuses on identifying, evaluating, and leading new investment opportunities and working closely with existing companies. Chris helps lead Madrona’s investments in companies innovating around the intersection of life and computer science through combining novel wet lab science with cutting-edge machine learning. He also helps lead investing activities in consumer technology and commerce, marketplaces, and Web3, focusing on how new technological innovations can create new consumer experiences and interactions with the digital world. Topics: - Evolution of the "Intersections of Innovation"…

Pioneer Square Labs' Greg Gottesman Forecasts Generative AI Will Transform Venture Capital Operations by 2033

Greg Gottesman of Pioneer Square Labs predicts venture capital will fundamentally change in the next 5-10 years, increasingly leveraging generative AI to provide startups with more than just funding, including operational and coding support. Sheila Gulati of Tola Capital adds that early-stage investing is becoming more democratized, with a broader investor pool amid the recent AI-driven revival in venture capital.

Investor Spotlight: Chris Picardo on Cross-Disciplinary Innovation and Finding Unique Founders

In this episode of Founded & Funded, host Coral Garnick Ducken interviews Madrona Partner Chris Picardo for the latest Investor Spotlight. With degrees in math and English, Chris shares his unique journey into venture capital. Chris highlights the importance of cross-disciplinary skills in understanding and communicating complex concepts and what he looks for in founders, emphasizing unique worldviews and innovative approaches, particularly in AI, biotech, and consumer verticals. This is a great episode for entrepreneurs interested in working with VCs. (00:00) Introduction to Madrona Partner Chris Picardo (00:46) Chris Picardo: From Math and English to Startups (01:26) Chris's Transition to…

Madrona investors say ETHDenver shows surging Web3 momentum, talent exodus from Web2, and new startup opportunities

Madrona Venture Group investors Maria Gilfoyle and Chris Picardo report strong momentum for Web3 after attending ETHDenver, noting growing consumer behavior shifts, new app categories, and a large talent migration from Web2 to Web3. They highlight the Pacific Northwest's relevance to Web3 and identify talent movement, future Ethereum work, and startup opportunities as key takeaways.

A-Alpha Bio raises $20M Series A led by Madrona to expand Seattle lab and scale protein-discovery platform

University of Washington spinout A-Alpha Bio raised $20 million in Series A funding led by Madrona Venture Group to expand downtown Seattle lab space and grow its machine-learning team for its protein-discovery platform. The company combines computational tools and yeast-based experiments to generate large protein-interaction datasets used to predict therapeutic protein candidates for diseases including COVID-19.

Aseem Datar leaves Microsoft to join Madrona Venture Group as partner; Madrona promotes Chris Picardo and hires Birkan Uzun; Jaime Teevan promoted to Microsoft CVP

Microsoft Azure GM and COO Aseem Datar is leaving Microsoft to join Madrona Venture Group as a partner later this month, while Madrona also promoted Chris Picardo to partner and hired Birkan Uzun as an investor; separately, Microsoft promoted Chief Scientist Jaime Teevan to corporate vice president. The article notes Datar’s 17+ years at Microsoft and prior roles, Picardo’s and Uzun’s backgrounds, and Teevan’s reaction to her promotion.

Organizations

See all 15
  • Aizen Therapeutics Board Member 2024–present · current
  • Institute for Protein Design Board Observer 2024–present · current
  • Stealth Biotech Board Member 2024–present · current

Education

  • Williams College Bachelor of Arts (B.A.), Mathematics and English · 2009–2013

Online